# DORIAN evolving neuroimaging

### status of the initiative








#### **DORIAN** (Diagnosis ORlented ANalysis)

DORIAN delivers a fast and reliable tool for the quantification of medical imaging to support the early and differential diagnosis of neurodegenerative disorders. It provides clinicians and researchers with state-of-the-art robust, rater-independent and reproducible quantitative biomarkers to better evaluate the  $\beta$ -amyloid load in brain tissue, complementing their ability to write an informed medical report and improve on the early detection and diagnosis of neurodegenerative diseases.

#### Dorian recent & next timepoints

- > Meet in Italy 4 Lifesciences
- > Smartcup Regione Liguria | UNIGE StartCup
- > Premio Nazionale per l'innovazione
- > BIOGEN meeting
- > First business contract
- > Fondazione spin-off
- > HoSession @ Nucl. Med. school in Neurology
- > HoSession @ EANM | Talk @ EADC



#### Dorian system



- Client app
- Back-end server
- Computing




(monitoring) > Second opinion for ELM same REARCE. ELMs and draw interval 22 REAR R75 areas R752206. R78 and draw interval 22 R742 early diagnosis of Report 2 Alzheimer' disease EDZENO > GDPR compliant \_  $\nabla \Delta X \Delta \nabla$ > 20 min. / analysis remote analysis connect / upload get results (farm / cloud)




#### Desktop client





#### Desktop client



#### Collaboration with AIMN

#### **DORIAN - BRAIN SOFTWARE PROJECT**

 $\rightarrow$  Host (& maintain) and give access to multiple research tools (amyloid-PET, FDG-PET, DATSPECT, MRI?)

 $\rightarrow$  Collect metadata / images into the first italian (normative)-database of amyloid PET images

 $\rightarrow$  Minimum image quality requirements (harmonization of acq. protocols)

 $\rightarrow$  Results visualization discussion





	Metadata for this exam	
Patient Name		
Birth Date	27/01/2020	
Education	0.30	
Patient Gender	OF OM OU	
Initial subjective symptomatology	Memory       Language       Visuospatial       Executive       Apraxy       Attention       ☑ Other         (specify)	
Pre-PET clinical suspicion	□ MCI □ PossAD □ ProbAD (85%+) □ FTLD □ VAD □ DLB 🗹 Other (non-specified dementio)	
Comorbidity	Diabetes 🗌 Cardiopathy 🗌 Arterious hypertension 🗌 Major internal organ disease 🗌 Depression 🗹 Non-specified	
Evidence of atrophy (MRI)	○Not avail. ○No ●Yes (specify)	
Evidence of hypometaboism (FDGPET)	● Not avaiL ○ No ○ Yes	
MMSE	0.30	
Amyloid-PET tracer	Florbetopir +	ŧ
Notes		



#### Dorian







"Standard" atlas - cortical 25 contralateral + 1 regions




"Clinical" atlas - most explored in clinical reading
label region
1 frontal (no basal area)
2 occipital
3 posterior parietal
4 temporal-lateral (no mesial-temporal)
5 striatus
6 thalamus
7 precuneus + posterior cingulate cortex

Data-driven atlas

IN PROGRESS..

DORIAN evolving neuroimaging



A template for each amyloid  $(^{18}F)$ tracer, built from EADC PET-2 initiative data (~50 amyloid neg / pos).

ANTS iterative registration (multivariate template construction, 20851191). Registered on MNI by ADNI temolate from flarhetaair



flutemetamol

 $\rightarrow$  will be submitted as a paper


#### Registration & quality check



 $\rightarrow$  ANTS: PET / PET + CT (antsRegistrationSyN), CT on CT template (<u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376197/</u>) and transform applied to corresponding PET

- 1. Multiscale registration
- 2. Rigid + affine
- 3. MNI atlases / parcellations warped to target PET

 $\rightarrow$  Convolutional network classifier trained on good / bad registration





## DORIAN evolving neuroimaging

Thank you